Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) reports the results of the company's Annual General Meeting (AGM) held on May 1, 2013. The filing confirms that all shareholder resolutions were passed. The document serves as a report of foreign issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance metrics.
Material Changes and Voting Results
Shareholders approved all 25 resolutions presented at the AGM. Key voting outcomes include:
- Financial Statements: Adoption of the Directors' Report and Financial Statements received 98.86% support.
- Remuneration: Approval of the Remuneration Report received 94.55% support, with 5.45% voting against.
- Board Elections: All director elections and re-elections were approved with support ranging from 97.80% to 99.92%. Notably, Sir Crispin Davis did not stand for re-election and stepped down from the Board effective the conclusion of the AGM.
- Special Resolutions: Authorities to allot shares, disapply pre-emption rights, and purchase own shares were approved with majorities exceeding 98%.
Shareholder participation remained consistent with the prior year, with 76.50% of issued share capital (excluding Treasury Shares) represented by votes cast and withheld, compared to 76.91% in 2012.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future operations, or specific risk factors. The document is limited to the announcement of AGM results and contact information for media and investor inquiries.
Investor Verification Checklist
- Verify the departure of Sir Crispin Davis from the Board and any subsequent succession planning.
- Review the full Remuneration Report to understand the context of the 5.45% dissenting vote.
- Confirm the specific terms of the share buyback authority and allotment powers granted by shareholders.
- Check the company website (www.gsk.com) for the detailed financial statements referenced in Resolution 1.